This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gevo Wins Stay In Federal Court Of Appeals Freeing It To Sell Into Any Market; Butamax's Attempts To Hinder Gevo With Legal Maneuvers Fail Again

ENGLEWOOD, Colo., Aug. 13, 2012 /PRNewswire/ -- Gevo, Inc. (NASDAQ: GEVO), a leading renewable chemicals and next-generation biofuels company, announced today that the Federal Circuit Court of Appeals granted Gevo's motion to stay a status quo order entered on July 6 th by the U.S. District Court in Delaware. The status quo order had prohibited Gevo from selling bio-isobutanol to the automotive fuels market pending Butamax Advanced Biofuels, LLC's (Butamax) appeal of the District Court's decision denying its motion for preliminary injunction.  In granting Gevo's motion, the Appeals court determined that Gevo had, at a minimum, "established a substantial case on the merits."

"We're delighted that the Federal Appeals court sided with Gevo and reversed the status quo order, which we believe was wrongly granted," said Brett Lund, Executive Vice President and General Counsel for Gevo. "We're once again free to sell to anyone anywhere." 

"We also find it surprising that Butamax is pursuing an appeal of the District Court's opinion denying the motion for a preliminary injunction against Gevo. In denying that motion, the District Court stated that Butamax likely 'does not hold a valid patent nor would the defendant (Gevo) infringe if it did,'" Lund commented.  "We see their appeal, two requests for status quo orders, the request for a Preliminary Injunction to shut down our commercial-scale production and the ongoing lawsuits as a blatant attempt by Butamax and its parent companies to slow us down and give themselves some chance to reduce our multi-year lead in commercialization of bio-isobutanol."

"We remain firm in our position that we have developed a unique and commercially viable technology and have never infringed on Butamax's technology because we simply don't need it. We have independently developed the industry leading technologies that we believe are not covered by their patents and are more effective than their efforts," Lund said. "We remain focused on our commercialization efforts and are encouraged by our string of victories in District Court and Federal Appeals Court."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,878.32 -49.88 -0.28%
S&P 500 2,088.43 -1.03 -0.05%
NASDAQ 4,935.2830 -4.0440 -0.08%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs